Table 1.

Demographics and clinical information for multiple sclerosis patients

Patient number	Age (years)	Sex	Duration of disease (years)	Type	Treatment	ARCS	EDSS
1	21	F	9	RRMS	Natalizumab	79	1.5
2	38	F	2	RRMS	Interferon beta-1a	100	0
3	57	F	4	RRMS	Betaferon	73	1.5
4	36	F	11	RRMS	Natalizumab	78	5.5
5	46	F	21	RRMS	Natalizumab	81	6.0
6	62	F	17	RRMS	Nil	72	6.5
7	40	F	16	RRMS	Natalizumab	82	1.5
8	51	F	26	RRMS	Nil	90	2.5
9	40	F	13	RRMS	Natalizumab	77	3.5
10	31	F	9	RRMS	Natalizumab	71	3.0
11	50	F	28	RRMS	Nil	96	2.5
12	36	F	4	RRMS	Natalizumab	83	1.0
13	46	F	4	RRMS	Fingolimod	86	1.5
14	59	F	22	RRMS	Fingolimod	60	1.5
15	36	F	4	RRMS	Interferon beta-1a	95	1.5
16	62	F	25	RRMS	Glatiramer	93	1.5
17	47	F	14	RRMS	Betaferon	92	1.0
18	31	F	9	RRMS	Natalizumab	79	1.5
19	28	F	11	RRMS	Natalizumab	93	1.5
20	48	F	5	RRMS	Immunoglobulin	111	3.5

ARCS audio recorded cognitive screen; EDSS extended disability status scale; F female; RRMS,relapsing remitting multiple sclerosis